Abstract
The messenger RNA vaccine against SARS-CoV-2 is effective at preventing COVID-19-associated hospitalization, and the Centers for Disease Control and Prevention has recommended vaccination for all eligible individuals. We demonstrate a case involving a patient who developed a life-threatening acute asthma exacerbation after receiving their third dose of the BNT16b2 vaccine. Because eosinophilia was observed after the second inoculation, it was considered likely that the patient had been sensitized to the BNT16b2 vaccine. Theoretically, the SARS-CoV-2 vaccine could trigger the exacerbation of asthma. It should be recognized that repeated SARS-CoV-2 vaccination may be a risk factor for the acute exacerbation of asthma.
Keywords: Adverse reaction; Eosinophils; SARS-CoV-2 vaccine, Acute asthma exacerbation; Sensitization.
【저자키워드】 eosinophils, Adverse reaction, Sensitization., SARS-CoV-2 vaccine, Acute asthma exacerbation, 【초록키워드】 SARS-CoV-2, Asthma, Vaccine, vaccination, Hospitalization, prevention, risk factor, SARS-CoV-2 vaccine, Patient, Control, SARS-CoV-2 vaccination, dose, sensitization, Messenger RNA, acute exacerbation, Adverse, life-threatening, center, eosinophilia, repeated, effective, the patient, receiving, individuals, eligible, the SARS-CoV-2, 【제목키워드】 Asthma, Vaccine, COVID-19 vaccine, BNT162b2, Pfizer-BioNTech, Messenger RNA, the SARS-CoV-2,